Andre Goy

Summary

Affiliation: Hackensack University Medical Center
Country: USA

Publications

  1. ncbi Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
    A Goy
    The Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
    Ann Oncol 20:520-5. 2009
  2. doi Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial
    Andre Goy
    The Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
    Leuk Lymphoma 51:1269-77. 2010
  3. ncbi Expanding therapeutic options in mantle cell lymphoma
    Andre Goy
    Lymphoma Division, Hackensack University Medical Center, NJ 07601, USA
    Clin Lymphoma Myeloma 7:S184-91. 2007
  4. doi Mantle cell lymphoma: the promise of new treatment options
    Andre Goy
    Lymphoma Division, John Theurer Cancer Center, Hackensack Medical University Cancer, NJ Center, Hackensack, 07601, USA
    Crit Rev Oncol Hematol 80:69-86. 2011
  5. ncbi New directions in the treatment of mantle cell lymphoma: an overview
    Andre Goy
    Hackensack University Medical Center, Hackensack, NJ 07601, USA
    Clin Lymphoma Myeloma 7:S24-32. 2006
  6. ncbi Mantle cell lymphoma: evolving novel options
    Andre Goy
    Lymphoma Division, Hackensack Medical University Cancer Center, 20 Prospect Avenue, Hackensack, NJ 07601, USA
    Curr Oncol Rep 9:391-8. 2007
  7. ncbi The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma
    Andre Goy
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 108:10-20. 2006
  8. doi Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
  9. ncbi High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    Jorge E Romaguera
    Department of Lymphoma, Unit 429, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:7013-23. 2005
  10. doi Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd 429, Houston, TX 77030, USA
    Br J Haematol 151:47-53. 2010

Detail Information

Publications42

  1. ncbi Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
    A Goy
    The Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
    Ann Oncol 20:520-5. 2009
    ..We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL)...
  2. doi Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial
    Andre Goy
    The Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
    Leuk Lymphoma 51:1269-77. 2010
    ..These biomarkers data begin to illuminate bortezomib's mechanism of action in lymphoma...
  3. ncbi Expanding therapeutic options in mantle cell lymphoma
    Andre Goy
    Lymphoma Division, Hackensack University Medical Center, NJ 07601, USA
    Clin Lymphoma Myeloma 7:S184-91. 2007
    ....
  4. doi Mantle cell lymphoma: the promise of new treatment options
    Andre Goy
    Lymphoma Division, John Theurer Cancer Center, Hackensack Medical University Cancer, NJ Center, Hackensack, 07601, USA
    Crit Rev Oncol Hematol 80:69-86. 2011
    ..g. bortezomib-R-chemo) to post-induction strategies such as consolidation (e.g. radioimmunotherapy, bortezomib) or maintenance therapy (e.g. rituximab, lenalidomide)...
  5. ncbi New directions in the treatment of mantle cell lymphoma: an overview
    Andre Goy
    Hackensack University Medical Center, Hackensack, NJ 07601, USA
    Clin Lymphoma Myeloma 7:S24-32. 2006
    ..A molecular approach to define biomarkers might help identify subgroups of patients and help develop rational therapies...
  6. ncbi Mantle cell lymphoma: evolving novel options
    Andre Goy
    Lymphoma Division, Hackensack Medical University Cancer Center, 20 Prospect Avenue, Hackensack, NJ 07601, USA
    Curr Oncol Rep 9:391-8. 2007
    ..Other small molecules have shown encouraging activity, including mTOR and Bcl-2 inhibitors, novel antibodies, and new cytotoxic agents. Future trials will also benefit from new molecular approaches through pharmacogenomics...
  7. ncbi The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma
    Andre Goy
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 108:10-20. 2006
    ..The results support the feasibility of FNA-based transcription profiles in patients with FL or LBCL, which, in combination with morphology and immunophenotyping, can help in the subtyping of these entities...
  8. doi Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
    ..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL...
  9. ncbi High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    Jorge E Romaguera
    Department of Lymphoma, Unit 429, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:7013-23. 2005
    ..To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL)...
  10. doi Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd 429, Houston, TX 77030, USA
    Br J Haematol 151:47-53. 2010
    ..In particular, there was no pulmonary or neurological dose-limiting toxicity, showing that bortezomib can be safely combined with R-HyperCVAD and R-M/A...
  11. ncbi Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
    Andre Goy
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
    J Clin Oncol 23:667-75. 2005
    ..Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma...
  12. pmc Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Anas Younes
    Departments of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4123-8. 2012
    ..Our results demonstrate that the addition of rituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL. These data are currently being confirmed in a multicenter randomized trial...
  13. ncbi Establishment and characterization of a new mantle cell lymphoma cell line M-1
    Andre Goy
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Leuk Lymphoma 45:1255-60. 2004
    ..The characterization of a new mantle cell lymphoma cell line is a unique tool for studying the biology of this subtype of lymphoma for which only a few cell lines have been established...
  14. ncbi Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:831-6. 2008
    ..The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL...
  15. doi Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressi
    Fredrick Hagemeister
    University of Texas M D Anderson Cancer Center UTMDACC, Houston, TX 77030, USA
    Br J Haematol 162:631-8. 2013
    ..This enhanced activity probably reflects VCR dose intensification, pharmacokinetic optimization, and enhanced delivery afforded by VSLI. A Phase 3 trial of R-CHMP versus R-CHOP in elderly patients with untreated DLBCL is ongoing...
  16. ncbi Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
    Anas Younes
    Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Eur J Cancer 42:2976-81. 2006
    ..Pegfilgrastim was found to be safe in support of ABVD chemotherapy that is administered every 14 d. Pegfilgrastim was also effective in maintaining ABVD dose intensity, and keeping planned dose of chemotherapy on schedule...
  17. ncbi Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma
    Barbara Pro
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Lymphoma 47:481-5. 2006
    ..In these previously treated patients with NHL, a single dose of pegfilgrastim was effective in promoting neutrophil count recovery after paclitaxel and topotecan, and allowed patients to receive the next planned dose on time...
  18. ncbi Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
    Nam H Dang
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    J Clin Oncol 22:4095-102. 2004
    ..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL...
  19. ncbi Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
    Michael Wang
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 165:510-8. 2014
    ..Future studies evaluating everolimus in a less refractory population or in combination with other targeted therapies in refractory MCL are warranted. ..
  20. ncbi Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
    Tatyana Feldman
    John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
    Br J Haematol 166:77-83. 2014
    ..Combining lenalidomide with RICE is feasible, and results in promising response rates (particularly complete response rates) in high-risk DLBCL patients. ..
  21. ncbi Update on the proteasome inhibitor bortezomib in hematologic malignancies
    Andre Goy
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Lymphoma 4:230-7. 2004
    ..Bortezomib represents an excellent example of how progress in understanding the biology of cancer cells can impact clinical practice and lead toward a new era of rational therapeutics...
  22. ncbi Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large
    Anthony Mato
    Lymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
    Leuk Lymphoma 54:2606-12. 2013
    ..Future work will focus on identifying molecular markers for failure in patients with DLBCL treated with dose-intensive regimens...
  23. ncbi Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD
    Anthony R Mato
    John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA
    Cancer 118:3565-70. 2012
    ....
  24. ncbi Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations
    Andre Goy
    Departments of Lymphoma, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Lab Invest 83:913-6. 2003
  25. pmc Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside
    Anthony R Mato
    Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA
    Oncologist 17:694-707. 2012
    ..The results of these studies will help our understanding about how to best integrate proteasome inhibition in the management of NHL and continue to improve patient outcomes...
  26. ncbi A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
    Anas Younes
    Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:310-4. 2003
    ..Rituximab is used to primarily deplete normal B cells from HD lesions...
  27. ncbi Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
    Nam H Dang
    MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 10:1513-8. 2003
    ..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications...
  28. doi Bortezomib in mantle cell lymphoma
    K Stephen Suh
    Jurist Research Center, 30 Prospect Avenue, Hackensack NJ 07601, USA
    Future Oncol 4:149-68. 2008
    ..An obvious effort is needed to enroll patients on clinical trials, the design of which might benefit from pharmacogenomics and a better understanding of MCL biology and its diversity...
  29. ncbi Ovarian cancer biomarkers for molecular biosensors and translational medicine
    K Stephen Suh
    Tissue Bank and Cancer Research Program, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA
    Expert Rev Mol Diagn 10:1069-83. 2010
    ..The article also presents a global view of all known potential biomarkers and mutations for ovarian cancer from NCI's Cancer Gene Index developed by Sophic, and Sanger's Catalogue of Somatic Mutations in Cancer database...
  30. pmc Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
    Rajendra Gharbaran
    John Theurer Cancer Center, Hackensack University Medical Center, d, Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ 07601, USA
    J Hematol Oncol 6:62. 2013
    ....
  31. ncbi Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
    Michael L Wang
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 369:507-16. 2013
    ..In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma...
  32. ncbi Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma
    George Z Rassidakis
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2213-20. 2003
    ..Future studies should explore the underlying molecular mechanisms of MUC-1 expression in these tumors and its role as a target for novel therapeutic strategies...
  33. ncbi Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma
    Ellen J Schlette
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:1682-8. 2004
    ..The frequency and prognostic significance of survivin expression in anaplastic large-cell lymphoma (ALCL) is unknown. Materials and..
  34. ncbi The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation
    Michele L Donato
    John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey Electronic address
    Biol Blood Marrow Transplant 20:1211-6. 2014
    ..aGVHD is significantly deleterious to OS and progression-free survival, whereas cGVHD is strongly favorable, supporting an important role for the graft-versus-myeloma effect. ..
  35. doi The role of the ubiquitin proteasome system in lymphoma
    K Stephen Suh
    John Theurer Cancer Center, Hackensack University Medical Center, NJ 07601, United States
    Crit Rev Oncol Hematol 87:306-22. 2013
    ....
  36. ncbi Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 97:586-91. 2003
    ..The impact of endoscopic assessment on the management of MCL patients is unknown...
  37. ncbi Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues
    Daniel H Silverman
    Department of Nuclear Medicine, UCLA Medical Center, Los Angeles, CA, USA
    Cancer Treat Rev 30:165-72. 2004
    ..Therefore, in this review, we attempt to compare the relative merits of (Bexxar and Zevalin) and address important practical considerations that may influence patient and physician choices regarding treatment using these agents...
  38. ncbi Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Nam H Dang
    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Br J Haematol 138:502-5. 2007
    ..The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon...
  39. ncbi Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 134:391-8. 2006
    ..In fact, the development of an isolated cutaneous vasculitis may portend a better clinical response to bortezomib in some patients...
  40. ncbi Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma
    Eunice S Wang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6306, USA
    Cancer 98:1196-205. 2003
    ..In contrast, the safety and efficacy of intensive regimens have not been established for Burkitt lymphoma (BL), a highly aggressive lymphoma for which moderate-dose chemotherapy is substandard in the HIV-negative population...
  41. ncbi Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
    Nam H Dang
    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Br J Haematol 136:439-47. 2007
    ..Further studies of denileukin diftitox in combination with other agents are warranted in previously untreated and relapsed/refractory T-NHL...
  42. ncbi MUC-1 mucin protein expression in B-cell lymphomas
    Julie Teruya-Feldstein
    Department of Pathology, Cell Biology and Immunology Programs, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 11:28-32. 2003
    ..For all cases, MUC-1 mucin expression correlated with a previous history of lymphoma (p=0.003)...